Liver News and Research

RSS

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

The [Ryan] privatization proposal overlooks the fact that when it comes to rising health costs, Medicare is part of the solution, not the problem. ... Together with health care reform, Medicare can be the driver of innovation due to its sheer market share.

6 Jun 2011

New gene therapy may cure Type 1 diabetes

An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of curing a disease that affects 3 million Americans.

6 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Newly diagnosed cancer patients face hurdles in receiving oncologist's appointment

Newly diagnosed cancer patients frequently face hurdles in obtaining an appointment for care with an oncologist, according to new research from the Perelman School of Medicine at the University of Pennnsylvania that will be presented Saturday, June 4 at the 2011 annual meeting of American Society of Clinical Oncology.

4 Jun 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

By using mice lacking a crucial gene that controls the process of chromatin remodeling of cytokines including those responsible for inflammation and comparing them to normal wild type mice with the gene, researchers at the George Washington University School of Medicine and Health Sciences have shown that the gene, Mta1, is essential for the parasite Schistosoma haematobium to establish a productive infection and survival in the host.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Compassionate release programs for prisoners need to be reformed: Research

The nation's system of freeing some terminally ill prisoners on grounds of compassionate release is so riddled with medical flaws and procedural barriers that many potentially medically eligible inmates are dying behind bars, say UCSF researchers in a new study.

4 Jun 2011

Combinations of mother's body size, placental size can predict heart disease in men in later life: Study

Researchers investigating the foetal origins of chronic disease have discovered that combinations of a mother's body size and the shape and size of her baby's placenta can predict heart disease in men in later life.

4 Jun 2011

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

4 Jun 2011

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.

4 Jun 2011

Technology, expert training and real-time feedback improves Hepatitis C outcomes

Widely-available technology, expert training and real-time feedback helped ensure that patients treated for Hepatitis C in local communities did as well as patients treated at a university-based medical center, results of a new study funded by HHS' Agency for Healthcare Research and Quality show. The study is published in the June 2 online issue of the New England Journal of Medicine and in the June 9 print edition.

3 Jun 2011

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

3 Jun 2011

Liver News and Research

Unique clinical trial addresses important questions about treating AIDS-related cancers

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

New gene therapy may cure Type 1 diabetes

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Newly diagnosed cancer patients face hurdles in receiving oncologist's appointment

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Compassionate release programs for prisoners need to be reformed: Research

Combinations of mother's body size, placental size can predict heart disease in men in later life: Study

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

Technology, expert training and real-time feedback improves Hepatitis C outcomes

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News